The European Commission has approved deucravacitinib, a first-in-class, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. This treatment represents a new way of treating this chronic immune-mediated disease. 

The approval was based on results from the phase...